platinum has been researched along with Fatigue in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Balar, A; Campbell, M; Galsky, MD; Heath, EI; Hepp, Z; Mazerolle, F; McGregor, B; McKay, C; O'Donnell, PH; Petrylak, D; Quinn, DI; Regnault, A; Rosenberg, J; Steinberg, J; Yu, EY | 1 |
| Bowering, V; Chang, K; Dhani, NC; Karakasis, K; Kavak, N; Lheureux, S; Madariaga, A; Mitchell, SA; Oza, AM; Pittman, T; Quintos, J; Ramsahai, J; Wang, L; Welch, SA | 1 |
| Burger, RA; Coleman, RL; Depasquale, SE; Gabrail, NY; Gersh, RH; Ghamande, SA; Gilbert, L; Harb, WA; Konstantinopoulos, PA; Kutarska, E; Leamon, CP; Lovejoy, CD; Messmann, RA; Morgenstern, DE; Naumann, RW; Nowara, E; Penson, RT; Sausville, EA; Symanowski, JT; Teneriello, MG | 1 |
3 trial(s) available for platinum and Fatigue
| Article | Year |
|---|---|
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
Topics: Adult; Antibodies, Monoclonal; Carcinoma, Transitional Cell; Fatigue; Female; Humans; Immune Checkpoint Inhibitors; Male; Pain; Platinum; Programmed Cell Death 1 Receptor; Quality of Life; Urinary Bladder Neoplasms | 2022 |
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian ca
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fatigue; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum | 2022 |
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Topics: Administration, Intravenous; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Folic Acid; Humans; Kaplan-Meier Estimate; Middle Aged; Nausea; Neutropenia; Oligopeptides; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Treatment Outcome; Vinca Alkaloids | 2013 |